PubMed Health⌕ Search

Biomedical subjects

C Hankins

Publications and source records attributed to C Hankins.

At least 19 recordsLinked to original sources
PubMed2002

The role of prisons in the HIV epidemic among female injecting drug users.

The objective of this study was to describe factors associated with imprisonment of female injecting drug users (IDUs) and to assess if female IDUs who have been in prison have different HIV risk behaviours when compared to females IDUs who have never been incarcerated. A seroepidemiological survey was conducted of 304 female IDUs recruited in outreach and treatment programmes in Madrid, Spain. Data on sociodemographic characteristics and recent and lifetime risk factors, sexual and reproductive history and history of imprisonment were collected. Bivariate analysis and a logistic regression model were used to identify factors associated with imprisonment. Risk factors for imprisonment were having illegal sources of income, not having a fixed address, leaving education before finishing primary school and starting injection of drugs early in adolescence. HIV risk behaviours were highly prevalent among this population of female IDUs and drug injection in prison was reported by more than one-third of those who had ever been imprisoned. In addition, recent HIV risk behaviour indicators were not associated with imprisonment, suggesting that incarceration did not lead to risk reduction after release from prison. Female IDUs who have been in prison have substantial reproductive health problems that require gynaecological care. These results point to the urgent need for prevention programmes which address HIV and other blood-borne infections using gender specific approaches for women IDUs incarcerated in Spanish prisons.

Adult↗
PubMed2001

Nonisotopic detection of human papillomavirus DNA in clinical specimens using a consensus PCR and a generic probe mix in an enzyme-linked immunosorbent assay format.

We assessed the value of a new digoxigenin (DIG)-labeled generic probe mix in a PCR-enzyme-linked immunosorbent assay format to screen for the presence of human papillomavirus (HPV) DNA amplified from clinical specimens. After screening with this new generic assay is performed, HPV DNA-positive samples can be directly genotyped using a reverse blotting method with product from the same PCR amplification. DNA from 287 genital specimens was amplified via PCR using biotin-labeled consensus primers directed to the L1 gene. HPV amplicons were captured on a streptavidin-coated microwell plate (MWP) and detected with a DIG-labeled HPV generic probe mix consisting of nested L1 fragments from types 11, 16, 18, and 51. Coamplification and detection of human DNA with biotinylated beta-globin primers served as a control for both sample adequacy and PCR amplification. All specimens were genotyped using a reverse line blot assay (13). Results for the generic assay using MWPs and a DIG-labeled HPV generic probe mix (DIG-MWP generic probe assay) were compared with results from a previous analysis using dot blots with a radiolabeled nested generic probe mix and type-specific probes for genotyping. The DIG-MWP generic probe assay resulted in high intralaboratory concordance in genotyping results (88% versus 73% agreement using traditional methods). There were 207 HPV-positive results using the DIG-MWP method and 196 positives using the radiolabeled generic probe technique, suggesting slightly improved sensitivity. Only one sample failed to test positive with the DIG-MWP generic probe assay in spite of a positive genotyping result. Concordance between the two laboratories was nearly 87%. Approximately 6% of samples that were positive or borderline when tested with the DIG-MWP generic probe assay were not detected with the HPV type-specific panel, perhaps representing very rare or novel HPV types. This new method is easier to perform than traditional generic probe techniques and uses more objective interpretation criteria, making it useful in studies of HPV natural history.

Cervix Uteri↗
PubMed2000

Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.

Various regimens of antiretroviral (ARV) therapy during pregnancy and labour have been found to be effective in reducing the risk of mother-to-child transmission of HIV. Cost and late identification of women with HIV infection during pregnancy in many developing countries have been the impetus to study inexpensive, short-course ARV regimens. Recently, it was shown that a single dose of nevirapine given orally once during labour to the mother and once to the infant greatly reduces the risk of HIV transmission. As a result, it has been proposed that in high HIV prevalence areas, this drug regimen be offered routinely to all pregnant women and their infants, without the need for an HIV test. This is seen as a cost-effective alternative to trying to make voluntary HIV testing and counselling universally available to pregnant women, which would require improved antenatal uptake and care, high uptake of HIV testing and high rates of return to learn results before women could make decisions regarding ARV prophylaxis. The ethical dilemmas arising from both these options are currently under debate, against a backdrop of concerns about breastfeeding and breastmilk substitutes, what to do about the increasing numbers of AIDS orphans and how to prevent HIV transmission to women in the first place.

Anti-HIV Agents↗
PubMed2000

Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis.

Persistent human papillomavirus (HPV) infection of the uterine cervix is a risk factor for progression to high-grade squamous intraepithelial lesions. Detection in consecutive genital samples of HPV-16 DNA, a frequently encountered HPV type, may represent persistent infection or reinfection. We undertook a study using PCR-single-strand conformation polymorphism (SSCP) analysis and sequencing of PCR products (PCR-sequencing) to determine if consecutive HPV-16-positive samples contained the same HPV-16 variant. Fifty women (36 human immunodeficiency virus [HIV] seropositive, 14 HIV seronegative) had at least two consecutive genital specimens obtained at 6-month intervals that contained HPV-16 DNA as determined by a consensus L1 PCR assay. A total of 144 samples were amplified with two primer pairs for SSCP analysis of the entire long control region. Fifteen different SSCP patterns were identified in our population, while 22 variants were identified by PCR-sequencing. The most frequent SSCP pattern was found in 75 (53%) samples from 27 (54%) women. The SSCP patterns obtained from consecutive specimens were identical for 46 (92%) of 50 women, suggesting persistent infection. Four women exhibited in consecutive specimens different HPV-16 SSCP patterns that were all confirmed by PCR-sequencing. The additional information on the nature of persistent infection provided by molecular variant analysis was useful for 6% of women, since three of the four women who did not have identical consecutive specimens would have been misclassified as having persistent HPV-16 infection on the basis of HPV typing.

Adult↗
PubMed1999

Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group.

BACKGROUND: Concurrent infection with HIV and human papillomavirus (HPV) in women is associated with increased rates of cervical dysplasia and shorter survival following the development of cervical cancer. The authors examined risk factors for HPV infection at study entry in HIV-positive women enrolled in the Canadian Women's HIV Study, a prospective open cohort study. METHODS: Subjects eligible for this analysis included the 375 HIV-positive women in the Canadian Women's HIV Study for whom HPV test results were available. Questionnaires on behavioural and clinical information, Pap smears, cervicovaginal lavage specimens and vaginal tampon specimens for HPV detection and typing by polymerase chain reaction were obtained at study entry. RESULTS: Overall, 67.2% (252/375) of the women were HPV-positive; the global prevalence of intermediate- and high-risk oncogenic HPV types was 49.1% (184/375). Women with squamous cell dysplasia (32/294) were more likely to have HPV infection than those without dysplasia (90.6% v. 62.6%; p = 0.002). Multivariate logistic regression analysis, with adjustment for number of lifetime partners and history of STD, revealed that the following risk factors were independently associated with HPV infection: CD4 count of less than 0.20 x 10(9)/L (adjusted odds ratio [OR] 1.99 [95% confidence interval (Cl) 1.17-3.37 (p = 0.011)]), non-white race (adjusted OR 2.00 [95% Cl 1.17-3.42 (p = 0.011)]), inconsistent condom use in the 6 months before study entry (adjusted OR 2.02 [95% Cl 1.16-3.50 (p = 0.013)]), and lower age, with women age 30-39 years (adjusted OR 0.51 [95% Cl 0.30-0.87 (p = 0.013)]) and age 40 years or older (adjusted OR 0.52 [95% Cl 0.26-1.01 (p = 0.052)]) compared with women less than 30 years of age. INTERPRETATION: Close monitoring for HPV-related effects is warranted in all HIV-positive women, particularly younger, non-white women who do not always use condoms. Counselling for women living with HIV, particularly younger women, should emphasize the importance of regular cytological screening, with increasing frequency as the CD4 count falls.

Adolescent↗
PubMed1999

Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group.

The line blot assay, a gene amplification method that combines PCR with nonisotopic detection of amplified DNA, was evaluated for its ability to detect human papillomavirus (HPV) DNA in genital specimens. Processed samples were amplified with biotin-labeled primers for HPV detection (primers MY09, MY11, and HMB01) and for beta-globin detection (primers PC03 and PC04). Amplified DNA products were hybridized by a reverse blot method with oligonucleotide probe mixtures fixed on a strip that allowed the identification of 27 HPV genotypes. The line blot assay was compared to a standard consensus PCR test in which HPV amplicons were detected with radiolabeled probes in a dot blot assay. Two hundred fifty-five cervicovaginal lavage specimens and cervical scrapings were tested in parallel by both PCR tests. The line blot assay consistently detected 25 copies of HPV type 18 per run. The overall positivity for the DNA of HPV types detectable by both methods was 37.7% (96 of 255 samples) by the line blot assay, whereas it was 43. 5% (111 of 255 samples) by the standard consensus PCR assay. The sensitivity and specificity of the line blot assay reached 84.7% (94 of 111 samples) and 98.6% (142 of 144 samples), respectively. The agreement for HPV typing between the two PCR assays reached 83.9% (214 of 255 samples). Of the 37 samples with discrepant results, 33 (89%) were resolved by avoiding coamplification of beta-globin and modifying the amplification parameters. With these modifications, the line blot assay compared favorably to an assay that used radiolabeled probes. Its convenience allows the faster analysis of samples for large-scale epidemiological studies. Also, the increased probe spectrum in this single hybridization assay permits more complete type discrimination.

Cervix Uteri↗
PubMed1998

Participation in clinical trials among women living with HIV in Canada. Canadian Women's HIV Study Group.

BACKGROUND: To describe participation in clinical trials among HIV-positive women enrolled since 1993 in the Canadian Women's HIV Study, a prospective open cohort study. METHODS: All HIV-positive women being followed at hospital-based or community-based clinics at 28 sites in 11 Canadian cities were eligible to participate in the Canadian Women's HIV Study. Baseline and follow-up information was collected for 413 women every 6 months by study nurses using standardized questionnaires. Data included sociodemographic variables, HIV exposure group, CD4 count, disease classification, use of antiretroviral therapies and participation in clinical trials. RESULTS: At study intake 15.0% (62/413) of the women had participated in a clinical trial; an additional 8.5% (35/413) participated during a median follow-up of 18 months. Multivariate analysis revealed that the following factors were independently associated with participation in a clinical trial: white race (adjusted odds ratio [OR] 3.38, p = 0.001), current use of antiretroviral therapy (adjusted OR 2.01, p = 0.008), completion of secondary school (adjusted OR 1.97, p = 0.024) and residence in the Prairies or Atlantic provinces (adjusted OR 1.98, p = 0.043). INTERPRETATION: Although the overall clinical trial participation rate of 23.5% was relatively high among HIV-positive women, injection drug users were underrepresented in this study population, and non-white women, women who did not complete high school and women not receiving antiretroviral therapy were less likely than white women, women of higher education and women receiving antiretroviral therapy to participate in clinical trials in Canada. Because of the importance of trial participants being representative of the population for which therapeutic agents are intended, HIV clinical trials must recruit women with lower literacy levels, non-white women, women not receiving antiretroviral therapy and women who are injection drug users to ensure generalizability of research findings. Further study is needed to assess factors that act as barriers and motivators to women's participation in HIV clinical trials.

Adult↗
PubMed1998

Sexual behavior and pregnancy outcome in HIV-infected women. Canadian Women's HIV Study Group.

Sexual behavior and pregnancy outcome data for 392 HIV-infected women were analyzed. During the 6 months before study entry, 71.2% (279 of 392 women) were sexually active. In multivariate regression, women with baseline CD4+ > or = 200/microl were more likely than women with CD4+ < 200/microl to be sexually active (adjusted odds ratio [OR] = 1.75; 95% confidence interval [CI], 1.06-2.88; p = .03). Consistent condom use was reported with 58.4% (149 of 255) of steady male partners and 65.7% (23 of 35) of casual partners. Overall, 90.3% of 279 sexually active women were using contraception. Among women aged between 15 and 44 years (n = 320), the incidence of pregnancy in the year before HIV diagnosis was 27.5 per 100 person-years (PY) (95% CI, 22.1-33.9) compared with 8.3/100 PY (95% CI, 6.8-10.2) in the time since HIV diagnosis (p < .001). The incidence of therapeutic termination of pregnancies conceived in the 20 weeks before HIV diagnosis (10.6/100 PY) was more than triple that after diagnosis (3.1/100 PY; p = .001). After publication of results of zidovudine prophylaxis of mother-to-child transmission, pregnancy rates did not increase, but the incidence of therapeutic abortion dropped from 4.3/100 PY to 1.4/100 PY (p = .009). Knowledge of sexual behavior, including pregnancy frequency and outcome, can assist in tailoring counseling for HIV-infected women concerning sexual and reproductive health.

Abortion, Therapeutic↗
PubMed1998

Changes in patterns of risk.

Against the background of debate about the nature of risk in relation to HIV transmission, and resultant changes in risk discourse from risk group to risk behaviour to risk situation, declines in the velocity of HIV spread are being documented in countries with high levels of political commitment and multi-sectoral approaches. Biological markers of sexual activity such as sexually transmitted disease incidence and HIV prevalence corroborate reports that young adults in Uganda and Thailand are increasingly adopting preventive behaviours. Risk perception, perceived social and community norms and self-efficacy influence behavioural change, but structural and contextual factors, including resource constraints affecting HIV prevention programmes and the treatment of sexually transmitted diseases, and social marginalization and stigmatization affecting access of vulnerable populations to the means of prevention play determinant roles. Both patterns of risk for HIV infection and our understanding of them are evolving. More research is required to gain knowledge and understanding of factors such as partner concurrency as well as cultural and socio-economic determinants and contextual underpinnings of sexual and drug injecting networks. This is an essential first step to mobilizing communities to take action at the individual, partnership and community levels to reduce risk.

Adult↗
PubMed1998

Socioeconomic geographical links to human immunodeficiency virus seroprevalence among childbearing women in Montreal, 1989-1993.

BACKGROUND: To describe the socioeconomic profiles of geographical areas on Montreal Island in which human immunodeficiency virus (HIV) seropositive women delivering live births between 1989 and 1993 reside. METHODS: Leftover dried blood spot filter paper specimens collected from newborns were irretrievably unlinked from identifying information prior to testing. Seroprevalence estimates were calculated based on Western blot confirmed positive samples. Using data from the Canadian census, Revenue Canada, and provincial birth records, the socioeconomic characteristics of postal zones in which seropositive mothers reside were described. RESULTS: Montreal Island had an overall 5-year HIV seroprevalence rate estimate of 16.6 (95% CI: 14.1-19.3) per 10000 childbearing women. Areas in which at least one seropositive woman gave birth had lower mean infant birthweights and higher percentages of single mothers and single-parent families. The HIV-positive neonatal blood specimens were more likely to originate from areas where a higher proportion of residents reported less education, greater unemployment, and lower income. CONCLUSIONS: Higher HIV infection rates were found among childbearing women from lower socioeconomic areas of Montreal. Increased understanding of the relationship between socioeconomic status and HIV acquisition and transmission is required to inform the development of targeted HIV prevention programmes.

Adult↗
PubMed1997

Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group.

The aim of the study was to compare the accuracy of self-administered vaginal tampon (VT) specimens for the detection of human papillomaviruses (HPVs) with that of cervicovaginal lavage specimens (CVL). Two hundred seventy-four paired VT and CVL specimens were collected prospectively from women at risk of sexually transmitted diseases. Specimens were treated and amplified with the polymerase chain reaction (PCR). Each woman served as her own control. One hundred and forty-four of 272 (52.9%) CVLs and 159 of 271 (58.7%) VTs contained HPV DNA sequences (correlation of 88%). The sensitivity and specificity of vaginal tampons reached 93.9% (138/147) and 80.5% (99/123), respectively. HPV typing results were concordant for 99 negative paired samples and 114 paired samples positive for the same type(s) (correlation of 78.9%). It is concluded that these sampling methods collect cells from different areas of the genital epithelium, highlighting the importance of further assessment of the comparative predictive value of HPV detection in each sample.

Adult↗
PubMed1997

Evaluation of a non-isotopic polymerase chain reaction assay for detection in clinical specimens of herpes simplex virus type 2 DNA. Canadian Women's HIV Study Group.

BACKGROUND: PCR assays for detection of herpes simplex virus DNA sequences in clinical specimens are more sensitive than cell culture. OBJECTIVE: A non-isotopic PCR assay (glycoprotein B HSV-2 assay, Roche Molecular Systems) for detection of HSV-2 DNA sequences was evaluated on 234 clinical specimens. STUDY DESIGN: A total of 125 patients (73 women, 40 men, 12 unknown) provided 162 samples contained in viral transport medium. Samples were first inoculated in cell culture, centrifuged at 12,000 x g, lyzed and kept frozen. A total of 77 women provided 42 cervicovaginal lavages and 30 vaginal tampons that were lyzed, tested with two isotopic HSV-2 PCR assays and kept frozen. All these samples were subsequently thawed and amplified with the glycoprotein B HSV-2 assay using generic primers for HSV glycoprotein B gene. Amplicons were captured on microplates with a HSV-2-specific probe and were detected with avidin-peroxidase and substrate. RESULTS: Of the 162 samples submitted to viral culture, HSV-2 was isolated from 73 while 89 did not contain HSV-2. All the 73 specimens with culture-proven HSV-2 infections tested positive with glycoprotein B HSV-2 assay (sensitivity of 100%). Herpesviruses other than HSV-2 were isolated from 34 samples that were negative with glycoprotein B HSV-2 assay. Two culture-negative samples tested positive in the glycoprotein B HSV-2 assay (specificity of 98.7%). The latter samples could not be retested in confirmatory isotopic HSV-2 PCR tests. HSV-2 DNA sequences could also be detected directly in cervical lavages or vaginal tampons from 13 women with the glycoprotein B HSV-2 assay. CONCLUSION: Detection and typing of HSV-2 in clinical samples, including those collected in viral transport medium, can be accomplished with PCR assays using the AMPLICOR format.

Cervix Uteri↗
PubMed1997

Sexuality in Montreal women living with HIV.

The impact of learning a positive HIV test result on the sexuality of 161 women (47 injection drug users (IDU), 53 non-IDU women of Haitian or African origin (non-IDU-HA), and 61 non-IDU Caucasian women (non-IDU-C) was assessed using closed and open-ended questions. Self-reported CD4+ count correlated with any post-test (p = 0.001) and past month sexual activity (p = 0.007). After learning their HIV status, 110 women (68%) were sexually active, 48 (44%) of these within 1 month. After resuming sexual activity, 84% underwent a sexual adjustment period (median duration 8.5 months). IDU women were more likely to have frequent sex, be anorgasmic, and prefer sex less often. Consistent partner condom use was low in general (19% for IDU, 30% for non-IDU-HA, and 62% for non-IDU-C) and by partner type (new regular partner 58%, same regular partner 36%, casual partner 29%). Sexual satisfaction tended to decline post-test and then increase to higher than pre-test levels. Counselling focused on the safe and satisfying aspects of sex may assist women with HIV infection in sexual decision-making. Facilitating the access of IDU women with HIV infection to medically supervised drug provision and to detoxification and rehabilitation programmes can weaken the link between drug use and sex work.

Adolescent↗